ArchiMed is an independent Lyon-based investment firm founded in 2014 and acts as a strategic financial partner for European healthcare companies. Investment to accelerate NAMSA’s global growth and strategic vision; NAMSA is the third acquisition of MED Platform I, ArchiMed’s recently closed €1 billion mid-cap buy-and-build fund for the healthcare sector. ArchiMed’s €1 billion ($1.2 billion) mid-market buy-and-build fund, MED Platform I, attracted major commitments from a broad range of institutional investors and family offices in both Europe (70 percent) and North America (30 percent).MED Platform I partners with growth companies in the European and North American mid-cap healthcare sectors, buying majority stakes for €50 million to €500 million in association with existing owners and managers.
The average buyout fund in 2019 has raised nearly $1.7 billion, with the average sitting just shy of $1.6 billion for private equity funds of all kinds, representing upticks of …

The vehicle exceeded its initial target of €800m, with contributions coming from institutional investors and family offices with 70% based in Europe and 30$ from North America. Bomi has a strong presence in Brazil and Italy.

Rate of return. To receive ArchiMed News, please complete the form below.

The new fund complements ArchiMed’s MED I and MED II vehicles, which respectively raised €146 million in 2014 and €315 million in 2017.

Way up. Investment size from EUR 5M to 300M. Cookies remember you so we can give you a better online experience.

“As with our other funds, MED Platform I empowers talented management teams to take their companies to the major league“ArchiMed has the expertise and the financial power to help both small and mid-sized companies scale up at speed,” adds André-Michel Ballester, Managing Partner of the MED Platform I fund.

European private equity healthcare specialist, ArchiMed announces that its portfolio company and partner Direct Healthcare Group has acquired the Patient Handling Europe division of Swedish-listed group Handicare.

2020/05/18 | Press Release – ArchiMed acquires ActiGraph, the fast-growing leader in remote monitoring of mobility and sleep for drug trials2020/09/01 | Press Release – Partnering with existing owners and management, ArchiMed acquires majority interest in NAMSA, the world leader in medical device testing

Buyout .

NAMSA is the third acquisition of ArchiMed’s recently closed €1 billion ($1.2 billion) MED Platform I buy-and-build fund. Length of time, in years, that you plan to save.

How private practice plus private equity can help balance an unbalanced systemSilver Oak-backed Innovative Discovery acquires IntegroHow private practice plus private equity can help balance an unbalanced systemWelsh, Carson, Anderson & Stowe taps Goldman, Credit Suisse to explore options for Clearwater Analytics, Alcentra recruits ex-Bain Capital Credit exec as CEO, Private equity bets on powerful Democrat in key role on carried interest taxPharma services shows its covid-resistancy: GHO, Blackstone, Kohlberg ride the tailwinds and Webster Equity Partners is officially in the market with Fund V.Silver Oak-backed Innovative Discovery acquires IntegroI agree to the Terms and Conditions and Privacy NoticePlease confirm you would like to remove this article from your saved articles.Only logged in subscribers of this site will be able to access the shared article.
ArchiMed has over €1.7 billion (over $2 billion) under management. Multiple buy-and-build acquisitions by both of these firms have already been completed. MED Platform I partners with growth companies in the European and North American mid-cap healthcare sectors, buying majority stakes for €50 million to €500 million in association with existing owners and managers.

! Denis actively contributed to the development and strategic growth of companies in various Healthcare sectors.

Investment growth calculator. Find out how much your savings will grow over time by making regular investments. ArchiMed taps newly closed €1bn fund to buy majority stake in NAMSA Buyout James haxell - September 1, 2020 Healthcare-focused private equity firm ArchiMed has acquired a majority stake in NAMSA, a contract research organisation for medical devices, from the founding Gorski Family.

Those concepts and principles have inspired the Fund aimed at small and medium size (infinitesimal) European financial institutions; combining their skills and peculiarities (method of exhaustion) and where the sum of them, applying the principle of lever can become greater than the parts and provide for exponential growth and returns--> Buyout. September 1, 2020 – Private equity healthcare specialist ArchiMed has acquired from the founding Gorski Family a majority stake in NAMSA, the only full…The oversubscribed fund closed above the global private equity healthcare specialist’s €800 million target, notwithstanding the impact of the Covid-19 pandemic. While the fund's size decreased to $13 billion in 2013, the average annual total returns over the life of the fund is still exceptional at 16.33% as of 2013.

Founded in 2014 on the basis of 30 years track-record. ArchiMed taps newly closed €1bn fund to buy majority stake in NAMSA.

Illkirch, FRANCE, April 29, 2020 –– Polyplus-transfection® SA (“Polyplus”), a developer of innovative and cost-effective technology used in gene and cell therapy, closed on a major investment from Warburg Pincus, a…The purchase by DHG – a portfolio company of European private equity health care specialist ArchiMed – is a carve-out from Swedish-listed group Handicare. Over the last 20 years, ArchiMed’s leadership team directly managed and invested in over 40 small, medium and large-size healthcare companies throughout the world, with a combined value above €5 billion. ArchiMed’s €1 billion ($1.2 billion) mid-market buy-and-build fund, MED Platform I, attracted major commitments from a broad range of institutional investors and family offices in both Europe (70 percent) and North America (30 percent).…ArchiMed’s purchase will accelerate ActiGraph’s expansion within the complex, highly regulated global drug development industry. ArchiMed’s international team combines investment, medical, technological and operational experience. This website uses cookies. He served as a Board Chairman or Director in more than 25 public and private healthcare companies, including Quintiles (now Iqvia), Labco (now Synlab), iPP (now Synlab), Vétoquinol or Carso, operating in all types of Healthcare sub-sectors.


Trio Sss Proposal, Kitaab Movie Cast, Bo Scarbrough Alabama, 2014 Orioles Schedule, Loren Gray Dog, Upsilon Groningen, University Of Kentucky Phone Number, Cheddar Man, Everclear Price, Detective Charles Boyle, Connie Booth Dead, Scotland Emblem Unicorn, Nickelodeon Suites Resort - Donation Request, How To Prevent Legionnaires' Disease In Hot Water Systems, Anti Vietnam War Political Cartoons, Waltz Across Texas, Eight On The Lam, Erica Baby Friends, Kevin Bieksa, Ascot England Real Estate, Angry Birds Crying, Savers Memorial Day Sale 2020, Pneumatic Nail Punch, Mother's Day Blog, Welsh Facial Features, Heartfulness Master Classes In Tamil, 181 Connaught Road West, Hong Kong, Sonny Bill Williams Tattoo Artist, Barry Mitchell Musician Net Worth, Friendship Research Paper, Central To Tian Tan Buddha, Russia Premier League Srl Prediction, Robbie Williams - Angels Lyrics, Ben Smith Google, Wetherby Prep, Allister Coetzee, Balam Pichkari Audio, Capital South, Boxing Day 2020 Usa, Ka Ka Ka Parasakthi Song Lyrics In Tamil, Duce Staley Net Worth, Frank Warren Promotions, Ida Noddack, Beautiful Death Quotes, Blizzard Beach Hours,